Par Launches Generic Lanoxin

Par Pharmaceuticals announced that it has begun shipments of Digoxin Tablets, the generic version of Covis‘ Lanoxin.

Digoxin is a cardiac glycoside indicated in adult patients for the treatment of mild to moderate heart failure and for ventricular rate control in chronic atrial fibrillation. In pediatric patients, it is indicated for increasing myocardial contractility in heart failure.

Digoxin inhibits Na+/K+ ATPase, an enzyme that regulates the quantity of sodium and potassium inside cells.

Inhibition of the enzyme leads to an increase in the intracellular concentration of sodium and thus (by stimulation of sodium-calcium exchange) an increase in the intracellular concentration of calcium.

Want to read more?